Clinical Trial Update: Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing CMAB807 injection to Prolia for efficacy and safety in postmenopausal osteoporosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• CMAB807
• Prolia (denosumab)

Snippet

Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd. | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED